...
首页> 外文期刊>Protein Expression and Purification >Expression and characterization of glycosylated and catalytically active recombinant human alpha-galactosidase a produced in Pichia pastoris
【24h】

Expression and characterization of glycosylated and catalytically active recombinant human alpha-galactosidase a produced in Pichia pastoris

机译:巴斯德毕赤酵母中产生的糖基化和具有催化活性的重组人α-半乳糖苷酶a的表达和表征

获取原文
获取原文并翻译 | 示例
           

摘要

Fabry disease is an X-linked inborn error of glycolipid metabolism caused by deficiency of the lysosomal enzyme alpha -galactosidase A. This enzyme is responsible for the hydrolysis of terminal alpha -galactoside linkages in various glycolipids. An improved method of production of recombinant alpha -galactosidase A for use in humans is needed in order to develop new approaches for enzyme therapy. Human alpha -galactosidase A for use in enzyme therapy has previously been obtained from human sources and from recombinant clones derived from human cells, CHO cells, and insect cells. In this report we describe the construction of clones of the methylotrophic yeast Pichia pastoris that produce recombinant human a-galactosidase A. Recombinant human alpha -galactosidase A is secreted by these Pichia clones and the level of production is more than 30-fold greater than that of previously used methods. Production was optimized using variations in temperature, pH, cDNA copy number, and other variables using shake flasks and a bioreactor. Expression of the human enzyme increased with increasing cDNA copy slumber at 25 degreesC, but not at the standard growth temperature of 30 degreesC. The recombinant alpha -galactosidase A was purified to homogeneity using ion exchange (POROS 20 CM, POROS 20 HQ) and hydrophobic (Toso-ether, Toso-butyl) chromatography with a BioCAD HPLC Workstation. Purified recombinant alpha -galactosidase A was taken up by fibroblasts derived from Fabry disease patients and normal enzyme levels could be restored under these conditions. Analysis of the carbohydrate present on the recombinant enzyme indicated the predominant presence of N-linked high-mannose structures rather than complex carbohydrates. (C) 2000 Academic Press. [References: 18]
机译:法布里病是由溶酶体酶α-半乳糖苷酶A缺乏引起的糖脂代谢的X连锁先天性错误。这种酶负责水解各种糖脂中的末端α-半乳糖苷键。为了开发用于酶治疗的新方法,需要一种用于人的重组α-半乳糖苷酶A的生产方法。用于酶疗法的人α-半乳糖苷酶A先前已从人来源以及从人细胞,CHO细胞和昆虫细胞衍生的重组克隆中获得。在本报告中,我们描述了生产重组人α-半乳糖苷酶A的甲基营养酵母巴斯德毕赤酵母克隆的构建。这些毕赤酵母克隆分泌了重组人α-半乳糖苷酶A,生产水平比其高30倍以上。以前使用的方法。利用摇瓶和生物反应器,利用温度,pH,cDNA拷贝数和其他变量的变化来优化生产。人类酶的表达随着cDNA复制的增加而增加,在25摄氏度,而不是在30摄氏度的标准生长温度下。使用离子交换(POROS 20 CM,POROS 20 HQ)和疏水色谱法(Toso-ether,Toso-butyl)和BioCAD HPLC工作站将重组α-半乳糖苷酶A纯化至均质。纯化的重组α-半乳糖苷酶A被来自Fabry病患者的成纤维细胞吸收,在这些条件下可以恢复正常的酶水平。对重组酶上存在的碳水化合物的分析表明,主要存在N连接的高甘露糖结构,而不是复杂的碳水化合物。 (C)2000学术出版社。 [参考:18]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号